Atara Biotherap (ATRA) Stock Price, Quote & News

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 623 4211

Website: www.atarabio.com

Address:

1280 Rancho Conejo Blvd, Thousand Oaks, United States

Smurfologist Jul. 3 at 4:22 PM

I love the way $ATRA has been slowly going up. And, even when it drops, it recovers nicely.......Gotta love this stock🙏🏾🐃💪🏾💣💥🚀

0 · Reply

VENIVICI Jun. 30 at 11:44 PM

$ATRA Time to offload the boat. Been dragging this bullet since the CRL... With no sign of that gap getting filled anytime soon it's probably time to let it go !!!!!!

2 · Reply

takingstock73 Jun. 23 at 9:24 PM

$ATRA anyone have a beat on when we can expect some news here ?

1 · Reply

TrkDvr Jun. 20 at 3:19 PM

$ATRA Looks like they'll need to do another funding round. Probably have been waiting for the FDA approval.

6 · Reply

ballyhooo Jun. 18 at 2:44 PM

$ATRA Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ

1 · Reply

VENIVICI Jun. 17 at 5:59 PM

$ATRA Does anyone know when the Type A meeting between ATRA and the FDA is scheduled? And any thoughts on how long it might take from the meeting to resubmission....

0 · Reply

BullRun4 Jun. 16 at 11:19 PM

$ATRA by when do they expect the FDA to give them a thumbs up and a go forward with approval? Q1 2026?

2 · Reply

takingstock73 Jun. 11 at 7:41 PM

$ATRA low vol sell off , this is a buying opportunity

0 · Reply

Smurfologist Jun. 10 at 12:53 PM

$ATRA Is $9.75 too much to ask for?!? TYME TO GAP UP!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Danny_vdw74 Jun. 9 at 5:36 PM

$ATRA 📅 Upcoming Events Annual Shareholders Meeting: The Annual Shareholders Meeting will take place on June 10, 2025, at 9:00 AM PDT. This is an important opportunity for shareholders to receive updates on the company's strategy, performance, and future outlook. --- 🧬 Clinical and Strategic Updates EBVALLO™ (tabelecleucel): The FDA has lifted the clinical hold, allowing Atara to resume the Phase 3 ALLELE study for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD). In addition, a Type A meeting is scheduled for Q2 2025 to discuss the approach for the resubmission of the Biologics License Application (BLA) for potential FDA approval.

0 · Reply

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 15, 2025, 8:35 AM EDT - 7 weeks ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:30 AM EDT - 7 weeks ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 5, 2025, 5:06 PM EDT - 2 months ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Mar 7, 2025, 4:01 PM EST - 4 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 1, 2025, 11:00 AM EST - 4 months ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 5 months ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 14, 2025, 8:11 AM EST - 5 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 11, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 5 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 9, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 7, 2025, 4:01 PM EST - 5 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 6, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 5, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 4, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 3, 2025, 11:00 AM EST - 5 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 7:00 AM EST - 5 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 30, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 29, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 28, 2025, 11:00 AM EST - 5 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 7:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

Jan 28, 2025, 3:23 AM EST - 5 months ago

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Jan 27, 2025, 8:30 PM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Jan 21, 2025, 1:11 PM EST - 5 months ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Jan 21, 2025, 7:30 AM EST - 5 months ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Jan 21, 2025, 12:21 AM EST - 5 months ago

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 16, 2025, 8:41 AM EST - 6 months ago

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Jan 16, 2025, 8:30 AM EST - 6 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Nov 27, 2024, 4:01 PM EST - 7 months ago

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Nov 13, 2024, 4:01 PM EST - 8 months ago

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:01 PM EST - 8 months ago

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Nov 5, 2024, 4:01 PM EST - 8 months ago

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Sep 4, 2024, 4:01 PM EDT - 10 months ago

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:16 PM EDT - 10 months ago

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Aug 12, 2024, 5:00 PM EDT - 11 months ago

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Smurfologist Jul. 3 at 4:22 PM

I love the way $ATRA has been slowly going up. And, even when it drops, it recovers nicely.......Gotta love this stock🙏🏾🐃💪🏾💣💥🚀

0 · Reply

VENIVICI Jun. 30 at 11:44 PM

$ATRA Time to offload the boat. Been dragging this bullet since the CRL... With no sign of that gap getting filled anytime soon it's probably time to let it go !!!!!!

2 · Reply

takingstock73 Jun. 23 at 9:24 PM

$ATRA anyone have a beat on when we can expect some news here ?

1 · Reply

TrkDvr Jun. 20 at 3:19 PM

$ATRA Looks like they'll need to do another funding round. Probably have been waiting for the FDA approval.

6 · Reply

ballyhooo Jun. 18 at 2:44 PM

$ATRA Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ

1 · Reply

VENIVICI Jun. 17 at 5:59 PM

$ATRA Does anyone know when the Type A meeting between ATRA and the FDA is scheduled? And any thoughts on how long it might take from the meeting to resubmission....

0 · Reply

BullRun4 Jun. 16 at 11:19 PM

$ATRA by when do they expect the FDA to give them a thumbs up and a go forward with approval? Q1 2026?

2 · Reply

takingstock73 Jun. 11 at 7:41 PM

$ATRA low vol sell off , this is a buying opportunity

0 · Reply

Smurfologist Jun. 10 at 12:53 PM

$ATRA Is $9.75 too much to ask for?!? TYME TO GAP UP!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Danny_vdw74 Jun. 9 at 5:36 PM

0 · Reply

Smurfologist Jun. 9 at 1:51 PM

$ATRA Is $9.75 too much to ask for on a Monday?!? LET'S GO!!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Vakeshka Jun. 8 at 4:40 PM

$ATRA institutions loading up. On May 16, 2025, Redmile Group, LLC executed a notable transaction involving Atara Biotherapeutics Inc. The firm added 263,506 shares of Atara Biotherapeutics Inc at a trade price of $6.84 per share. This strategic move highlights Redmile Group's continued interest in the biotechnology sector, particularly in companies with potential for transformative therapies. The transaction reflects a calculated decision to increase their stake in Atara Biotherapeutics, a company focused on developing treatments for serious diseases. The recent transaction increased Redmile Group's total holdings in Atara Biotherapeutics to 705,207 shares. This addition represents a 0.46% position in the firm's portfolio and a 9.90% stake in Atara Biotherapeutics. The transaction underscores Redmile Group's confidence in Atara Biotherapeutics' potential...By increasing its stake, Redmile Group aims to capitalize on the potential upside of Atara Biotherapeutics' innovative therapies

0 · Reply

ezimon Jun. 6 at 10:12 PM

$ATRA yes, in theory it should had been around $16 - $18 for the last 4 months, so it may be that it is catching up :-)

0 · Reply

Smurfologist Jun. 6 at 6:24 PM

$ATRA $9.25 is on the horizon after hitting $9.20......LET'S GO!!!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

hassle Jun. 6 at 6:03 PM

$ATRA there are no news whatsoever in the last 20 days, why this is constantly going up? anything i might be missing?

0 · Reply

Smurfologist Jun. 6 at 4:57 PM

$ATRA JUST PLAIN WoW!!! Next stop: $9.15?!?🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Jun. 6 at 3:08 PM

$ATRA is on the cusp of being a monster stock; yawl betta recognize!!! So Purdy!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Jun. 6 at 3:02 PM

$ATRA JUST WoW!!!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Jun. 6 at 2:31 PM

$ATRA Is $9.00 too much to ask for?!? LET'S GO!!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Jun. 6 at 1:46 PM

$ATRA Nice rise all week 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Jun. 5 at 5:05 PM

$ATRA Just WoW!!!🙏🏾💪🏾💣💥🚀

0 · Reply

Smurfologist Jun. 4 at 5:04 PM

$ATRA WoW!!!💪🏾💣💥🚀

0 · Reply

Market Cap	50.46M
Revenue (ttm)	128.94M
Net Income (ttm)	-85.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-66.23%
Debt to Equity Ratio	0.00

Volume	25,379
Avg Vol	57,608
Day's Range	N/A - N/A
Shares Out	5.96M
Stochastic %K	86%
Beta	0.18
Analysts	Sell
Price Target	$14.00